Associated Papers
Synchronous diagnosis of multicentric glioma with distinct isocitrate dehydrogenase molecular profiles: a case report.
Mohan AA et al.
Cns Oncology, 2026
A Case of IDH-Mutant Astrocytoma Harboring an IDH2 R172_H173delinsSN Variant.
Auen T et al.
Neuropathology : Official Journal of the Japanese Society of Neuropathology, 2026
Isocitrate Dehydrogenase Inhibitors in Acute Myeloid Leukemia.
Dai Q et al.
Chemistry & Biodiversity, 2026
Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trial.
Jones RL et al.
Nature Communications, 2026
Evaluation of the Idylla IDH1-2 Mutation Assay for the Detection of IDH Variants in Solid Tumors and Hematological Malignancies.
Gilson P et al.
International Journal of Molecular Sciences, 2026
Germline variants in ATM, BRCA2, other cancer predisposition and novel candidate genes are implicated in glioma risk in adult glioma patients with a familial or personal history of tumors.
Brand F et al.
Acta Neuropathologica, 2026
Autopalmitoylation of IDH1-R132H regulates its neomorphic activity in cancer cells.
Hu L et al.
Nature Chemical Biology, 2026
Clonal hematopoiesis associates with prevalent and incident cardiometabolic disease in a cardiac catheterization cohort.
Regan JA et al.
Plos One, 2026
Clonal architecture of FLT3-ITD and acquired 13q uniparental disomy define prognostic heterogeneity and therapeutic vulnerabilities in acute myeloid leukemia.
Lai A et al.
Neoplasia (new York, N.y.), 2025
Integrative machine learning-guided in silico and in vitro approach reveals selective small molecule inhibitors targeting mutant IDH1.
Bajaj M et al.
Rsc Advances, 2025
Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With Olutasidenib.
Chien KS et al.
Clinical Lymphoma, Myeloma & Leukemia, 2025
Ancestry-dependent patterns of somatic mosaicism and clonal hematopoiesis mutations in over 125,000 individuals reveal distinct cancer associations.
Colin-Leitzinger C et al.
Human Genomics, 2025
Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations.
Harding JJ et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Clonal hematopoiesis in apparent treatment-resistant hypertension, insights from multiple medical centers and community-based cohorts.
Lv C et al.
Nature Aging, 2025
Next-Generation Sequencing Reveals a Diagnostic and Prognostic Role of the TP53 R273C Mutation in Lower-Grade, IDH-Mutant Astrocytomas.
Navarro L et al.
International Journal of Molecular Sciences, 2025
Loss of IDH1 and IDH2 mutations during the evolution of metastatic chondrosarcoma.
Cross W et al.
Genome Biology, 2025
High depth targeted next-generation sequencing in vascular malformations.
Pakhathirathien P et al.
Human Molecular Genetics, 2025
Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations.
Nguyen MK et al.
The Oncologist, 2025
IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy.
Hoff FW et al.
Haematologica, 2025
Unveiling splicing disruptions due to common somatic variants in acute myeloid leukemia.
Morote-Faubel M et al.
Human Genomics, 2025
Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome.
Cortes JE et al.
Blood Advances, 2025
Utility of IDH1/2 mutations as biomarkers for detection of measurable residual disease in acute myeloid leukemia.
Boertjes EL et al.
Blood Advances, 2025
Molecular Landscape of Pediatric Low-Grade Gliomas: Insights From RNA-NGS and Bioinformatic Analysis.
Brož P et al.
Genes, Chromosomes & Cancer, 2025
Analysis of IDH1 and IDH2 mutations as causes of the hypermethylator phenotype in colorectal cancer.
Ward JC et al.
The Journal of Pathology, 2025
Analysis of cerebrospinal fluid tumor-derived DNA to obviate biopsy of IDH-mutant brainstem glioma in an adult.
Youssef M et al.
The Journal of Liquid Biopsy, 2025
Myeloid sarcoma shows a high frequency of mutations activating the MAPK/ERK pathway and association with clonal hematopoiesis.
Nann D et al.
The Journal of Pathology. Clinical Research, 2025
MutationAssessor in cBioPortal.
Su Y et al.
Biorxiv : the Preprint Server for Biology, 2025
Comprehensive Genomic Profiles of Melanoma in Veterans Compared to Reference Databases.
Mettman D et al.
Federal Practitioner : for the Health Care Professionals of the Va, Dod, and Phs, 2025
Distinct characteristics of lymphoid and myeloid clonal hematopoiesis in World Trade Center first responders.
Esai Selvan M et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations.
Nguyen MK et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Upfront liquid biopsy in patients with advanced solid tumors who were not feasible for tissue-based next-generation sequencing.
Fukuda A et al.
Japanese Journal of Clinical Oncology, 2025
A targeted next-generation sequencing panel for identification of clinically relevant mutation profiles in solid tumours.
Das K et al.
Scientific Reports, 2025
Clinicopathological and Molecular Profiling of Adult-Type Diffuse Glioma Using Immunohistochemistry and Real-Time Polymerase Chain Reaction: Study from a Tertiary Care Cancer Center in Western India.
Kaur K et al.
Neurology India, 2025
Clonal Hematopoiesis of Indeterminate Potential Is Associated With Incident Abdominal Aortic Aneurysm.
Tan Y et al.
Arteriosclerosis, Thrombosis, and Vascular Biology, 2025
Molecular analysis of adolescent and young adult high grade gliomas in the SPECTA-AYA study: Poorly characterised tumours with frequent germline alterations.
Morfouace M et al.
European Journal of Cancer (oxford, England : 1990), 2025
Reannotation of cancer mutations based on expressed RNA transcripts reveals functional non-coding mutations in melanoma.
Pepe D et al.
American Journal of Human Genetics, 2025
In-depth characterization of vaccine-induced neoantigen-specific T cells in patients with IDH1-mutant glioma undergoing personalized peptide vaccination.
Zelba H et al.
Journal for Immunotherapy of Cancer, 2025
Establishment and characterization of TK-DDCS1: a novel IDH1 mutated dedifferentiated chondrosarcoma cell line.
Saisuwan K et al.
Human Cell, 2025
Comprehensive analysis of clinical, pathological, and molecular features in chronic myelomonocytic leukemia: frequent ASXL1 and NRAS mutations and higher mutation burden in myeloproliferative CMML compared to myelodysplastic CMML.
Jeong Y
Leukemia & Lymphoma, 2025
Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AML.
Ikoma Y et al.
Leukemia, 2025
From Sanger to Oxford Nanopore MinION Technology: The Impact of Third-Generation Sequencing on Genetic Hematological Diagnosis.
Larráyoz MJ et al.
Cancers, 2025
IDH mutation and MGMT methylation status in glioblastoma and other gliomas patients: a Russian retrospective cohort study.
Eid M et al.
Journal of the Egyptian National Cancer Institute, 2025
Real-World Genomic Landscape of Gastrointestinal Cancers in Asia and the Middle East Using Comprehensive Circulating Tumor DNA Next-Generation Sequencing.
Muto M et al.
Oncology Research and Treatment, 2025
Clonal hematopoiesis is associated with distinct rheumatoid arthritis phenotypes.
Hiitola E et al.
Science Advances, 2025
Catalytically distinct metabolic enzyme isocitrate dehydrogenase 1 mutants tune phenotype severity in tumor models.
Schwartz AV et al.
The Journal of Biological Chemistry, 2025
IDH1 regulates human erythropoiesis by eliciting chromatin state reprogramming.
Li M et al.
Elife, 2025
Persistent postremission clonal hematopoiesis shapes the relapse trajectories of acute myeloid leukemia.
Chow RD et al.
Blood Advances, 2025